
Harmony Biosciences Holdings, Inc. – NASDAQ:HRMY
Harmony Biosciences Holdings stock price today
Harmony Biosciences Holdings stock price monthly change
Harmony Biosciences Holdings stock price quarterly change
Harmony Biosciences Holdings stock price yearly change
Harmony Biosciences Holdings key metrics
Market Cap | 1.94B |
Enterprise value | 1.83B |
P/E | 10.85 |
EV/Sales | 4.18 |
EV/EBITDA | 12.74 |
Price/Sales | 4.30 |
Price/Book | 4.67 |
PEG ratio | 0.02 |
EPS | 2.35 |
Revenue | 617.51M |
EBITDA | 236.88M |
Income | 137.70M |
Revenue Q/Q | 29.79% |
Revenue Y/Y | 30.92% |
Profit margin | 41.44% |
Oper. margin | 27.45% |
Gross margin | 80.93% |
EBIT margin | 27.45% |
EBITDA margin | 38.36% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeHarmony Biosciences Holdings stock price history
Harmony Biosciences Holdings stock forecast
Harmony Biosciences Holdings financial statements
$44.5
Potential upside: 21.08%
Analysts Price target
Financials & Ratios estimates
Jun 2023 | 134.21M | 34.3M | 25.56% |
---|---|---|---|
Sep 2023 | 160.26M | 38.46M | 24% |
Dec 2023 | 168.41M | 26.60M | 15.8% |
Mar 2024 | 154.61M | 38.33M | 24.79% |
Jun 2023 | 760183000 | 275.01M | 36.18% |
---|---|---|---|
Sep 2023 | 777766000 | 296.43M | 38.11% |
Dec 2023 | 811448000 | 344.45M | 42.45% |
Mar 2024 | 846985000 | 331.59M | 39.15% |
Jun 2023 | 37.06M | -7.77M | -339K |
---|---|---|---|
Sep 2023 | 63.1M | -813K | -55.09M |
Dec 2023 | 76.66M | -36.06M | -53.52M |
Mar 2024 | 31.14M | -6.18M | -3.63M |
Harmony Biosciences Holdings alternative data
Aug 2023 | 200 |
---|---|
Sep 2023 | 200 |
Oct 2023 | 200 |
Nov 2023 | 200 |
Dec 2023 | 200 |
Jan 2024 | 200 |
Feb 2024 | 200 |
Mar 2024 | 246 |
Apr 2024 | 246 |
May 2024 | 246 |
Jun 2024 | 246 |
Jul 2024 | 246 |
Harmony Biosciences Holdings other data
Period | Buy | Sel |
---|---|---|
Mar 2024 | 0 | 12173 |
Quarter | Transcript |
---|---|
Q1 2024 30 Apr 2024 | Q1 2024 Earnings Call Transcript |
Q4 2023 22 Feb 2024 | Q4 2023 Earnings Call Transcript |
Q3 2023 1 Nov 2023 | Q3 2023 Earnings Call Transcript |
Q2 2023 1 Aug 2023 | Q2 2023 Earnings Call Transcript |
Insider | Compensation |
---|---|
Mr. John Charles Jacobs M.B.A. (1967) Pres, Chief Executive Officer & Director | $933,940 |
Dr. Jeffrey M. Dayno M.D. (1957) Chief Medical Officer | $734,250 |
Mr. Jeffrey Dierks M.B.A. (1971) Chief Commercial Officer | $482,450 |
Mr. Jeffrey S. Aronin (1968) Founder & Non-Executive Chairman | $31,200 |
Alkermes: Additional Narcolepsy Data Could Lead The Way To The Next Stage
Harmony Stock Tanks On Study Miss For Narcolepsy Drug: Problems May Be Escalating
Amphastar Pharmaceuticals: Great Growth At A High Price
Harmony Biosciences: A Balancing Act As Investors Lose Some Sleep
Harmony Biosciences: Rare Low-Volume Accumulation With Short Squeeze Potential
Harmony Biosciences: A Company With Solid Fundamentals (Rating Upgrade)
Avadel Pharmaceuticals: Real-World Data Supports Market Opportunity For Lumryz
Harmony Biosciences: Why I Am Adding More Shares
Harmony Biosciences: Up 40% Since My Last Coverage, Waiting For Another Opportunity
-
What's the price of Harmony Biosciences Holdings stock today?
One share of Harmony Biosciences Holdings stock can currently be purchased for approximately $36.75.
-
When is Harmony Biosciences Holdings's next earnings date?
Unfortunately, Harmony Biosciences Holdings's (HRMY) next earnings date is currently unknown.
-
Does Harmony Biosciences Holdings pay dividends?
No, Harmony Biosciences Holdings does not pay dividends.
-
How much money does Harmony Biosciences Holdings make?
Harmony Biosciences Holdings has a market capitalization of 1.94B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 32.93% to 582.02M US dollars.
-
What is Harmony Biosciences Holdings's stock symbol?
Harmony Biosciences Holdings, Inc. is traded on the NASDAQ under the ticker symbol "HRMY".
-
What is Harmony Biosciences Holdings's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Harmony Biosciences Holdings?
Shares of Harmony Biosciences Holdings can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Harmony Biosciences Holdings's key executives?
Harmony Biosciences Holdings's management team includes the following people:
- Mr. John Charles Jacobs M.B.A. Pres, Chief Executive Officer & Director(age: 58, pay: $933,940)
- Dr. Jeffrey M. Dayno M.D. Chief Medical Officer(age: 68, pay: $734,250)
- Mr. Jeffrey Dierks M.B.A. Chief Commercial Officer(age: 54, pay: $482,450)
- Mr. Jeffrey S. Aronin Founder & Non-Executive Chairman(age: 57, pay: $31,200)
-
Is Harmony Biosciences Holdings founder-led company?
Yes, Harmony Biosciences Holdings is a company led by its founder Mr. Jeffrey S. Aronin.
-
How many employees does Harmony Biosciences Holdings have?
As Jul 2024, Harmony Biosciences Holdings employs 246 workers.
-
When Harmony Biosciences Holdings went public?
Harmony Biosciences Holdings, Inc. is publicly traded company for more then 5 years since IPO on 19 Aug 2020.
-
What is Harmony Biosciences Holdings's official website?
The official website for Harmony Biosciences Holdings is harmonybiosciences.com.
-
Where are Harmony Biosciences Holdings's headquarters?
Harmony Biosciences Holdings is headquartered at 630 West Germantown Pike, Plymouth Meeting, PA.
-
How can i contact Harmony Biosciences Holdings?
Harmony Biosciences Holdings's mailing address is 630 West Germantown Pike, Plymouth Meeting, PA and company can be reached via phone at +48 45399800.
-
What is Harmony Biosciences Holdings stock forecast & price target?
Based on 3 Wall Street analysts` predicted price targets for Harmony Biosciences Holdings in the last 12 months, the avarage price target is $44.5. The average price target represents a 21.08% change from the last price of $36.75.
Harmony Biosciences Holdings company profile:

Harmony Biosciences Holdings, Inc.
harmonybiosciences.comNASDAQ
246
Biotechnology
Healthcare
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
Plymouth Meeting, PA 19462
CIK: 0001802665
ISIN: US4131971040
CUSIP: 413197104